Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer

Author： Gershoni-Baruch R. Dagan E. Fried G. Bruchim Bar-Sade R. Sverdlov-Shiri R. Zelicksson G. Friedman E.

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.36, Iss.8, 2000-05, pp. : 983-986

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

By Comen E. Davids M. Kirchhoff T. Hudis C. Offit K. Robson M.

Breast Cancer Research and Treatment, Vol. 129, Iss. 1, 2011-08 ,pp. : 185-190

Springer Publishing Company

Access to resources Recommend Favorite

Oral contraceptive use and the risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations

By Gillanders William Simon Jr Peter

The Women's Oncology Review, Vol. 5, Iss. 2, 2005-06 ,pp. : 127-128

Informa Healthcare

Access to resources Recommend Favorite

Two founder BRCA2 mutations predispose to breast cancer in young women

By Infante Mar

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 567-571

Springer Publishing Company

Access to resources Recommend Favorite

Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study

By Leiserowitz Gary

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 35-36

Informa Healthcare

Access to resources Recommend Favorite

Founder BRCA 1 and 2 Mutations among a Consecutive Series of Ashkenazi Jewish Ovarian Cancer Patients

By Tobias D.H. Eng C. McCurdy L.D. Kalir T. Mandelli J. Dottino P.R. Cohen C.J.

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 148-151

Elsevier

Access to resources Recommend Favorite